See All Slides - tctmd.com

Slides

Presentation TCT 2012

Coronary Physiology and FFR

Presenter: William Fearon

October 25, 2012

Presentation TCT 2012

AIDA STEMI MRI: Cardiac MRI Substudy from a Prospective, Randomized Trial of Intracoronary Abciximab in Patients with ST-Segment Elevation Myocardial Infarction

Presenter: Holger Thiele

October 25, 2012

Presentation TCT 2012

SORT OUT IV 3-Year: A Prospective, Randomized Trial of Everolimus-Eluting vs. Sirolimus-Eluting Stents

Presenter: Lisette Okkels Jensen

October 25, 2012

Presentation TCT 2012

Patient Selection for PFO Closure: Who Should Be Treated Always, Sometimes, and Never?

Presenter: Jonathan Tobis

October 25, 2012

Presentation TCT 2012

The Misinterpretation of Clinical Trials: Common Errors and Case Examples

Presenter: Sanjay Kaul

October 25, 2012

Presentation TCT 2012

IVUS-Guided Reverse CART

Presenter: Yasushi Asakura

October 25, 2012

Presentation TCT 2012

HCM Management: What Do the Guidelines Say?

Presenter: Bernard Gersh

October 25, 2012

Presentation TCT 2012

Type II Endoleaks: Implications, Treatment, and Prevention

Presenter: Christopher Zarins

October 25, 2012

Presentation TCT 2012

Impact of Paclitaxel Formulation on Drug Transfer, Tissue Pharmacokinetics, and Biological Activity

Presenter: Juan Granada

October 25, 2012

Presentation TCT 2012

The Changing Nature of AAA Disease in the 21st Century

Presenter: Frank Criado

October 25, 2012

Advertisement

Slides

Coronary Physiology and FFR

AIDA STEMI MRI: Cardiac MRI Substudy from a Prospective, Randomized Trial of Intracoronary Abciximab in Patients with ST-Segment Elevation Myocardial Infarction

SORT OUT IV 3-Year: A Prospective, Randomized Trial of Everolimus-Eluting vs. Sirolimus-Eluting Stents

Patient Selection for PFO Closure: Who Should Be Treated Always, Sometimes, and Never?

The Misinterpretation of Clinical Trials: Common Errors and Case Examples

IVUS-Guided Reverse CART

HCM Management: What Do the Guidelines Say?

Type II Endoleaks: Implications, Treatment, and Prevention

Impact of Paclitaxel Formulation on Drug Transfer, Tissue Pharmacokinetics, and Biological Activity

The Changing Nature of AAA Disease in the 21st Century

Search Slides

Advertisement

Advertisement

Slides

Search Slides

Sign Up for Our Newsletter

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content